Systematic Review of Efficacy and Safety of Ofatumumab in Children with Difficult-to-Treat Nephrotic Syndrome

Publish Year: 1397
نوع سند: مقاله کنفرانسی
زبان: Persian
View: 404

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

CNAMED06_003

تاریخ نمایه سازی: 2 تیر 1397

Abstract:

Objectives: Different types of studies have been done so far on drugs efficacy and safety in children with refractory nephrotic syndrome. Ofatumumab might be an effective treatment for this syndrome; however, the long-term effects and cost-effectiveness of Ofatumumab treatment have not been comprehensively assessed. This study aims to do a systematic review on the efficacy and safety of Ofatumumab in children with difficult-to-treat nephrotic syndrome.Material and Methods: An electronic literature search was conducted to identify appropriate studies. The search term was: ( nephrotic syndrome or minimal change disease or focal segmental glomerulosclerosis or membranous) and (‘‘Ofatumumab’’ or‘‘CD20’’ or Arzerra or HuMax-CD20 ). We included all studies related to usingOfatumumab in children with difficult-to-treat nephrotic syndrome. Two independent reviewers extracted data from the articles according to the selection criteria.Results: Eligible studies were included in this systematic review. The literature search and reference mining yielded 77 potential relevant articles. We removed 32 articles because of duplication. Also, 26 references were excluded after reviewing the titles and abstracts because they were books, book sections, review papers and therefore not relevant. Then, we reviewed full-text of selected articles and removed 14 other studies because the topics were not relevant to the subject. At last, 5 studies were included in the systematic review. The metric considered to assess the efficacy of Ofatumumab in children with nephrotic syndrome in most of the studies was complete remission rate.Conclusions:Our systematic review shows thatOfatumumab may be effective in the treatment of refractory nephrotic syndrome in children, and it can reduce the use of steroid and immunosuppressants. However, acknowledging the limitations of the study due to the size and nature of the studies included, further large randomized trials are suggested.

Authors

Yalda Ravanshad

Clinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Mohammad Esmaeili

Department of Pediatric, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Anoush Azarfar

Department of Pediatric, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Batoul Osmani

Clinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran